Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Saudi Journal of Gastroenterology [The]. 2010; 16 (3): 194-197
in English | IMEMR | ID: emr-123576

ABSTRACT

Therapeutic intervention in nonalcoholic fatty liver disease are limited, while anti-oxidative materials have shown benefits in animal models. This study aimed to evaluate grape seed extract as an anti-oxidative material in this process. Therapeutic effects of grape seed extract were evaluated in comparison to vitamin C in a double-blind setting. Fifteen patients were enrolled in each group. Liver function tests were done; also, grade of steatosis and pattern of echogenicity of the liver were determined. Patients were followed up by the same evaluation repeated in first, second and third months. Mean age +/- standard deviation was 43.2 +/- 10.3 years. Grape seed extract [GSE] significantly improved the grade of fatty liver change; and resulted in significant decrease in alanine aminotransferase in patients receiving the concentrate compared to those receiving vitamin C independently, from the initial grade of steatosis. This study describes the beneficial effect of using grape seed extract for three months in patients with nonalcoholic fatty liver disease. These results may improve with a longer period of follow-up


Subject(s)
Humans , Male , Female , Liver Function Tests , Fatty Liver/drug therapy , Ascorbic Acid , Plants, Medicinal , Plant Extracts
2.
Pakistan Journal of Medical Sciences. 2009; 25 (1): 91-96
in English | IMEMR | ID: emr-92381

ABSTRACT

To find out whether homocysteine has a direct effect on bone or it is an innocent bystander? The study was designed to investigate probable role of homocysteine on bone mineral density [BMD]. This a case-control study wherein, 30 patients with at Least one densitometry criterion of osteoporosis in femoral neck or Lumbar spine were enrolled as the case group along with another 30 normal subjects with normal BMD, as the control group. The patients of the two groups were matched for their ages and sex. In all eligible patients BMD was measured by DEXA and fasting serum homocysteine level were measured by Enzyme Immunoassay Kit. The mean of serum level of homocysteine were 11.67 +/- 4.38 and 11.97 +/- 3.09 imol/l in control and case groups respectively. The difference between two groups was not significant [P=0.761]. Serum homocysteine level and BMC of various areas in case and control groups had no significant correlation [lumbar spine in control group [r= 0.025, p=0.9], lumbar spine in case group [r=0.071, p=0.716], femoral neck in control group [r=0.276, p=0.147], femoral neck in case group [r=0.001, p=0.998fl. Despite numerous studies about direct effect of homocysteine on increase of osteoporotic fracture risk, our study did not show a correlation between serum Level of homocysteine and BMD. Due to multiplicity of factors affecting bone density, final conclusions need extensive investigations with attention to other confounding factors


Subject(s)
Humans , Female , Bone Density/genetics , Hyperhomocysteinemia/diagnosis , Hyperhomocysteinemia/etiology , Hyperhomocysteinemia/enzymology , Osteoporosis/etiology , Osteoporosis/diagnosis , Risk Factors , Fractures, Bone/etiology , Bone Diseases, Metabolic/epidemiology , Case-Control Studies , Homocysteine
SELECTION OF CITATIONS
SEARCH DETAIL